Skip to main content
Article thumbnail
Location of Repository

Quetiapine in the treatment of schizophrenia and related disorders

By Michael Riedel, Norbert Müller, Martin Strassnig, Ilja Spellmann, Emanuel Severus and Hans-Jürgen Möller

Abstract

Quetiapine was developed in 1985 by scientists at AstraZeneca (formerly Zeneca) Pharmaceuticals. It received official US Food and Drug Administration approval in September 1997 and approval in Germany in 2000. Since then, quetiapine has been used in the treatment of severe mental illness in approximately 70 countries including Canada, most Western European countries, and Japan. Quetiapine is a dibenzothiazepine derivative with a relatively broad receptor binding profile. It has major affinity to cerebral serotonergic (5HT2A), histaminergic (H1), and dopaminergic D1 and D2 receptors, moderate affinity to α1- und α2-adrenergic receptors, and minor affinity to muscarinergic M1 receptors; it demonstrates a substantial selectivity for the limbic system. This receptor occupancy profile with relatively higher affinity for the 5HT2A receptor compared with the D2 receptor is in part responsible for the antipsychotic characteristics and low incidence of extrapyramidal side-effects of quetiapine. The efficacy of quetiapine in reducing positive and negative symptoms of schizophrenia has been proven in several clinical trials with placebo-controlled comparators. Quetiapine has also demonstrated robust efficacy for treatment of cognitive, anxious-depressive, and aggressive symptoms in schizophrenia. Long-term trials show sustained tolerability for a broad spectrum of symptoms. Quetiapine has also proven efficacy and tolerability in the treatment of moderate to severe manic episodes, and in the treatment of juveniles with oppositional-defiant or conduct disorders, and in the geriatric dementia population. Recent data indicate that quetiapine may also be effective in the treatment of bipolar depressive symptoms without increasing the risk of triggering manic episodes, and in borderline personality disorder. In comparison with other antipsychotics, quetiapine has a favorable side-effect profile. In clinical trials only small insignificant prolongations of the QT interval were observed. Weight-gain liabilities and new-onset metabolic side-effects occupy a middle-ground among newer antipsychotics. As a result of its good efficacy and tolerability profile quetiapine has become well established in the treatment of schizophrenia and manic episodes

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2654633
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. 2007b.Effi cacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci.
    2. (1997). A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand,
    3. (2001). A comparison of the relative safety, effi cacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) Study. Clin Therapeutics,
    4. (2006). A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencieng an acute exacerbation requring hospitalization. Schizophr Res,
    5. (2002). A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.
    6. (2004). A liquid chromatographicelectrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: Application to a Study of In Vitro Metabolism.
    7. (2004). A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophenia: opening a closed book. Biol Psychiatry,
    8. (2000). A positron emission tomography study of quetiapine in schizophrenia: a preliminary fi nding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry,
    9. (2003). A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Therapeutics,
    10. (2004). A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
    11. (2005). A randomized, doubleblind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression.
    12. (1960). A rating scale for depression.
    13. (1989). A rating scale for drug-induced akathisia.
    14. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand,
    15. (1978). A rating scale for mania: reliability, validity and sensitivity.
    16. (2004). A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
    17. (2001). A study of quetiapine: effi cacy and tolerability in psychotic adolescents.
    18. (2004). A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.
    19. (1999). Adherence to antipsychotic medications.
    20. (2001). Antipsychotic drugs:prolonged QTc interval, torsade de pointes, and sudden death.
    21. (2003). Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
    22. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis.
    23. (2006). Are older antipsychotic drugs obsolete?
    24. (1998). Attentional improvement following quetiapine fumarate treatment in schizophrenia.
    25. (1999). Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci,
    26. (1997). BG; the Seroquel Trial 13 Study Group.
    27. (2000). Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci,
    28. (2001). Clinical pharmakokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet,
    29. (2005). Comparing effi cacy of fi rst-line atypical antipsychotics: no evidence of differential effi cacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.
    30. (2004). Comparison of quetiapine (“Seroquel”), olanzapine and risperidone in a randomized study in patients with schizophrenia. Presented at the XXIV Collegium Internationale Neuro-Psychopharmacologicum.
    31. (2006). Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, doubleblind, fl exible-dose, 8-week study.
    32. (2001). D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.
    33. (1996). Diabetes mellitus in schizophrenic patients.
    34. (2003). Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia.
    35. (2002). Does cognitive function improbe with quetiapine in comparison to haloperidol? Schizophr Res,
    36. (1976). ECDEU Assessment Manual for Psychopharmacology. Revised ed.
    37. (2005). Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia.
    38. (2002). Effect of fl uoxetine and imipramine on the pharmakokinetics and tolerability of the antipsychotic quetiapine.
    39. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    40. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    41. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    42. (2005). Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial.
    43. (2003). Effectiveness of Quetiapine up to 1.600 mg/day: Short-term Results with 14–month Follow-up. Poster presented at the 16th Congress of the European College of Neuropsychopharmacology.
    44. (2003). Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.
    45. (2007). Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci.
    46. (1999). Effi cacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res,
    47. (2005). Effi cacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacol Clin Exp,
    48. (2004). Effi cacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schiz Res,
    49. (2006). Effi cacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study.
    50. (2004). Effi cacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    51. (2005). Essential psychopharmacology. Neuroscientifi c basis and practical applications. 2nd ed.
    52. (1980). Extrapyramidal Symptom Rating Scale.
    53. (1996). ICI 204, 636, an atypical antipsychotic: effi cacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia.
    54. (2002). Improvement in cognitive functioning in patients with fi rst-episode psychosis during treatment with quetiapine: an interim analysis.
    55. (2004). Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
    56. (2001). Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.
    57. (2003). Long-term safety, tolerability, and clinical effi cacy of quetiapine in adolescents: an open-label extension trial.
    58. (2000). Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therapeutics,
    59. (2004). Maintenance of long-term effi cacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol,
    60. (2004). Maintenance treatment for schizophrenia with quetiapine. Hum Psychopharmacol Clin Exp,
    61. (2006). Minimising the risk of diabetes in patients with schizophrenia and bipolar disorder.
    62. (2004). Multiple dose pharmakokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia.
    63. (1982). Negative symptoms in schizophrenia.
    64. (2001). Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.
    65. (2003). New generation antipsychotic drugs and QTc interval prolongation.
    66. (2003). on behalf of the SPECTRUM study group,
    67. (1997). Pharmakokinetics and safety of lithium coadministered with Seroquel (quetiapine) [abstract]. Schizophr Res,
    68. (2000). Pharmakokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label-trial in adolescents with psychotic disorders.
    69. (2004). Preliminary Experience With Adjunctive Quetiapine In Patients Receiving Selective Serotonin Reuptake Inhibitors. Depr Anxiety,
    70. (2000). QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.
    71. (2003). Quality of life and body weight in community-dwelling schizophrenic patient. Schizophr Res,
    72. (2004). Quetiapine and Clozapine in Parkinsonian patients with dopaminergic psychosis.
    73. (2004). Quetiapine for schizophrenia. Cochr Datab Syst Rev,
    74. (2004). Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: a randomized, double-blind trial.
    75. (1999). Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today,
    76. (2004). Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol,
    77. (2005). Quetiapine has equivalent effi cacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci,
    78. (1997). Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo.
    79. (2004). Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety,
    80. (2002). Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res,
    81. (2001). Quetiapine is signifi cantly superior to haloperidol and placebo in improving mood in patients with schizophenia. Presented at the 7th World Congress of Biological Psychiatry,
    82. (2005). Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin,
    83. (2004). Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, doubleblind, placebo-controlled study. Bipolar Disord,
    84. (2002). Quetiapine: A 5-Year Update.
    85. (2002). Quetiapine: preclinical studies, pharmakokinetics, drug interactions, and dosing.
    86. (2002). Relationship between quetiapine dose and effi cacy. Presented at the 15th European College of Neuropsychopharmacology Congress.
    87. (2001). Review of atypical antipsychotics and weight gain.
    88. (2005). Self-reported body weight perception and dieting practices in community-dwelling schizophrenia patients. Schizophr Res,
    89. (2000). Single-dose pharmakokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry,
    90. (2004). Society Task Force on Rating Scales for Parkinson’s Disease.
    91. (1983). Spielberger’s State-Trait Anxiety Inventory: Measuring anxiety with and without an audience during performance on a stabilometer. Percept Mot Skills,
    92. (1962). The Brief Psychiatric Rating Scale. Psychol Rep,
    93. (2002). The effect of multiple dose of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders.
    94. (2004). The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res,
    95. (2003). The effi cacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of effi cacy. Schizophr Res,
    96. (2000). The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia.
    97. (1987). The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull,
    98. (2002). The safety and pharmakokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    99. (2000). Weight changes in patients treated with quetiapine. Presented at the 153rd annual meeting of the American Psychiatric Association. May 13–18;

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.